Heiko Maacke

1.1k total citations
21 papers, 902 citations indexed

About

Heiko Maacke is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Heiko Maacke has authored 21 papers receiving a total of 902 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 12 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Heiko Maacke's work include Lung Cancer Treatments and Mutations (7 papers), Melanoma and MAPK Pathways (5 papers) and Lung Cancer Research Studies (4 papers). Heiko Maacke is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Melanoma and MAPK Pathways (5 papers) and Lung Cancer Research Studies (4 papers). Heiko Maacke collaborates with scholars based in Switzerland, Germany and United States. Heiko Maacke's co-authors include Kirsten Jost, Sven Opitz, Holger Kalthoff, Stefan Miska, H W Stürzbecher, Wolfgang Deppert, Wilhelm Henning, Laura Hasselbach, Yate‐Ching Yuan and Jütta Lüttges and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Oncogene.

In The Last Decade

Heiko Maacke

20 papers receiving 882 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heiko Maacke Switzerland	14	656	493	152	127	92	21	902
David E. MacCallum United Kingdom	11	739 1.1×	472 1.0×	102 0.7×	96 0.8×	94 1.0×	21	1.1k
Rachel V. Pearline United States	5	756 1.2×	343 0.7×	135 0.9×	168 1.3×	73 0.8×	7	976
Nick Loizos United States	18	523 0.8×	192 0.4×	146 1.0×	74 0.6×	114 1.2×	29	870
P.N. Munster United States	12	307 0.5×	336 0.7×	119 0.8×	79 0.6×	72 0.8×	18	584
Azra Alvi United Kingdom	10	425 0.6×	503 1.0×	101 0.7×	100 0.8×	163 1.8×	10	823
P. Rudolph Germany	15	333 0.5×	302 0.6×	125 0.8×	154 1.2×	82 0.9×	28	697
Oriol Arpí Spain	15	359 0.5×	376 0.8×	126 0.8×	149 1.2×	61 0.7×	24	710
Shelly Gunn United States	12	445 0.7×	298 0.6×	91 0.6×	162 1.3×	119 1.3×	28	814
Ludovic Ménard United Kingdom	10	536 0.8×	235 0.5×	136 0.9×	92 0.7×	46 0.5×	15	786
Oday Hamid United States	15	669 1.0×	685 1.4×	201 1.3×	123 1.0×	211 2.3×	41	1.2k

Countries citing papers authored by Heiko Maacke

Since Specialization

Citations

This map shows the geographic impact of Heiko Maacke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heiko Maacke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heiko Maacke more than expected).

Fields of papers citing papers by Heiko Maacke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heiko Maacke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heiko Maacke. The network helps show where Heiko Maacke may publish in the future.

Co-authorship network of co-authors of Heiko Maacke

This figure shows the co-authorship network connecting the top 25 collaborators of Heiko Maacke. A scholar is included among the top collaborators of Heiko Maacke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heiko Maacke. Heiko Maacke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saad, Joseph, Roland Newman, Éric Durand, et al.. (2025). Predictors of response and rational combinations for the novel MCL ‐1 inhibitor MIK665 in acute myeloid leukemia. Molecular Oncology. 20(2). 389–408. 1 indexed citations

Hernández-García, Susana, Luís A. Corchete, Laura San‐Segundo, et al.. (2019). Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. Haematologica. 105(3). e116–e120. 42 indexed citations

Bardia, Aditya, Mrinal M. Gounder, Jordi Rodón, et al.. (2019). Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors withRAS/RAFAlterations. The Oncologist. 25(1). e160–e169. 69 indexed citations

Orozco, Olivia, Tinya J. Abrams, Jayesh Desai, et al.. (2018). Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies. Clinical Cancer Research. 24(14). 3465–3474. 18 indexed citations

Takahashi, Shunji, Takayuki Kobayashi, Junichi Tomomatsu, et al.. (2016). LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer. Cancer Chemotherapy and Pharmacology. 79(1). 131–138. 11 indexed citations

Watanabe, Koichiro, Satoshi Otsu, Yoshinori Hirashima, et al.. (2016). A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 77(6). 1157–1164. 27 indexed citations

Sullivan, Ryan J., Jeffrey S. Weber, Sapna P. Patel, et al.. (2015). A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment.. Journal of Clinical Oncology. 33(15_suppl). 9007–9007. 49 indexed citations

Juric, Dejan, Jean‐Charles Soria, Sunil Sharma, et al.. (2014). A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 9051–9051. 47 indexed citations

Banerji, Udai, Alan D. Smith, Andrea Zivi, et al.. (2014). Dual targeting of RAF-MEK-ERK and PI3K-AKT-mTOR pathways in RAS-mutant cancers: Preclinical insights and institutional experience from a clinical trial of binimetinib (MEK162) plus BYL719.. Journal of Clinical Oncology. 32(15_suppl). e13559–e13559. 3 indexed citations

10.

Felip, Enriqueta, Federico Rojo, Martin Reck, et al.. (2008). A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy. Clinical Cancer Research. 14(12). 3867–3874. 68 indexed citations

11.

Felip, Enriqueta, Federico Rojo, Martin Reck, et al.. (2006). Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: FISH results. Journal of Clinical Oncology. 24(18_suppl). 7160–7160. 6 indexed citations

12.

Rojo, Federico, Dorothee Foernzler, Barbara Klughammer, et al.. (2005). Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: preliminary results. Journal of Clinical Oncology. 23(16_suppl). 7100–7100. 1 indexed citations

13.

Felip, Enriqueta, Federico Rojo, Dorothee Foernzler, et al.. (2005). P-949 Phase II pharmacodynamic trial of erlotinib in advancednon-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy. Lung Cancer. 49. S369–S369. 1 indexed citations

14.

Maacke, Heiko, et al.. (2002). Autoantibodies in sera of pancreatic cancer patients identify recombination factor Rad51 as a tumour-associated antigen. Journal of Cancer Research and Clinical Oncology. 128(4). 219–222. 36 indexed citations

15.

Maacke, Heiko, Sven Opitz, Kirsten Jost, et al.. (2000). Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. International Journal of Cancer. 88(6). 907–913. 178 indexed citations

16.

Maacke, Heiko, Kirsten Jost, Sven Opitz, et al.. (2000). DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene. 19(23). 2791–2795. 180 indexed citations

17.

Maacke, Heiko, Wolff Schmiegel, Christian Roeder, et al.. (1997). Overexpression of p53 protein during pancreatitis. British Journal of Cancer. 75(10). 1501–1504. 33 indexed citations

18.

Henning, Wilhelm, et al.. (1997). MDM2 is a target of simian virus 40 in cellular transformation and during lytic infection. Journal of Virology. 71(10). 7609–7618. 26 indexed citations

19.

Zhang, Suisheng, Heiko Maacke, & Frank Große. (1995). Molecular Cloning of the Gene Encoding Nuclear DNA Helicase II. A BOVINE HOMOLOGUE OF HUMAN RNA HELICASE A AND DROSOPHILA Mle PROTEIN. Journal of Biological Chemistry. 270(27). 16422–16427. 55 indexed citations

20.

Steinmeyer, Klaus, Heiko Maacke, & Wolfgang Deppert. (1990). Cell cycle control by p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. I. Regulation of p53 expression.. PubMed. 5(11). 1691–9. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact